Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...
Pharmaceutical Technology on MSN
FDA approves Celltrion’s Eydenzelt for eye diseases
Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...
REGENXBIO completed enrollment in its ATMOSPHERE and ASCENT trials that will be evaluating surabgene lomparvovec (sura-vec, ...
The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the ...
Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies ...
New research links TGF-β1 to maladaptive bone marrow endothelial cell repair and shows that blocking its pathway can restore haematopoietic function after transplant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback